Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TSC-203-A0201 |
| Trade Name | |
| Synonyms | TSC 203-A0201|TSC203-A0201 |
| Drug Descriptions |
TSC-203-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the PRAME antigen presented on HLA-A*02:01, which potentially induces proliferation of CD4+ and CD8+ T lymphocytes and enhances antitumor immune response (Cancer Immunol Res (2024) 12 (10_Supplement): B041). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TSC-200-A0201 + TSC-203-A0201 | TSC-200-A0201 TSC-203-A0201 | 0 | 1 |
| TSC-201-B0702 + TSC-203-A0201 | TSC-201-B0702 TSC-203-A0201 | 0 | 1 |
| TSC-203-A0201 | TSC-203-A0201 | 0 | 1 |
| TSC-203-A0201 + TSC-204-A0101 | TSC-203-A0201 TSC-204-A0101 | 0 | 1 |
| TSC-203-A0201 + TSC-204-A0201 | TSC-203-A0201 TSC-204-A0201 | 0 | 1 |
| TSC-203-A0201 + TSC-204-C0702 | TSC-203-A0201 TSC-204-C0702 | 0 | 1 |